NK1 antagonists

US9469629B2 · kind B2 · utility

Assignee

• OPKO Health, Inc. · US

Inventors

• Anandan Palani · Bound Brook, US
• Xianhai Huang · Hackettstown, US
• Dong Xiao · Hackettstown, US
• Sunil Paliwal · Manalapan, US
• Hon-Chung Tsui · East Brunswick Township, US
• Michelle Laci Wrobleski · Whitehouse Station, US
• Ashwin U. Rao · Avenel, US
• Cheng Wang · Fort Washington, US
• Sapna S. Shah · Jamesburg, US
• Neng-Yang Shih · Lexington, US

Key dates

• Filing date: Jun 13, 2014
• Grant date: Oct 18, 2016
• Expiry date: Jun 13, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound having the general structure shown in Formula I:or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.